BIOMAT Database Logo BIOMAT Database Logo

Properties of glycosylated and non-glycosylated human recombinant IGF binding protein-3 (IGFBP-3). 1993

A Sommer, and S K Spratt, and G P Tatsuno, and T Tressel, and R Lee, and C A Maack
Celtrix Pharmaceuticals, Inc., Santa Clara, California 95052.

The interaction of insulin-like growth factor-I with glycosylated and nonglycosylated human recombinant IGFBP-3 was studied by competition binding and by realtime biospecific interaction analysis (BIA). No significant difference was found in the affinity of the two forms of recombinant IGFBP-3 for IGF-I. Combining the results from the two different methods of binding analysis, a dissociation constant of 50 +/- 14 pM was determined. This value compares favorably to that reported for IGF-I binding to natural human plasma-derived IGFBP-3. Subcutaneous injection into rats of IGF-I either bound to glycosylated or nonglycosylated IGFBP-3 yielded an area under the curve (AUC) that was essentially the same for either form of IGFBP-3 and was twice as large as the AUC obtained after injection of IGF-I in the free form. Circulating IGF-I peak levels were reached in less than 1 h post-injection for free IGF-I, 4 and 8 h post-injection for the nonglycosylated and glycosylated IGF-I/IGFBP-3 complexes respectively. Neutral gel filtration of rat serum samples 4 and 8 h post-injection revealed that the IGF-I delivered bound to the nonglycosylated IGFBP-3 circulated as a 40-50 kDa complex at the 4 h time point and as a 130-140 kD complex at the 8 h time point. IGF-I delivered as a complex with glycosylated IGFBP-3 was found to circulate as a 140 kD complex at 4 and 8 h post-injection.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008297 Male Males
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002850 Chromatography, Gel Chromatography on non-ionic gels without regard to the mechanism of solute discrimination. Chromatography, Exclusion,Chromatography, Gel Permeation,Chromatography, Molecular Sieve,Gel Filtration,Gel Filtration Chromatography,Chromatography, Size Exclusion,Exclusion Chromatography,Gel Chromatography,Gel Permeation Chromatography,Molecular Sieve Chromatography,Chromatography, Gel Filtration,Exclusion Chromatography, Size,Filtration Chromatography, Gel,Filtration, Gel,Sieve Chromatography, Molecular,Size Exclusion Chromatography
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose

Related Publications

A Sommer, and S K Spratt, and G P Tatsuno, and T Tressel, and R Lee, and C A Maack
Developmentally regulated expression of IGF binding protein-3 (IGFBP-3) in human placental fibroblasts: effect of exogenous IGFBP-3 on IGF-1 action.
March 1996, Regulatory peptides,
A Sommer, and S K Spratt, and G P Tatsuno, and T Tressel, and R Lee, and C A Maack
Effects of recombinant human insulin-like growth factor (IGF)-I and estrogen administration on IGF-I, IGF binding protein (IGFBP)-2, and IGFBP-3 in anorexia nervosa: a randomized-controlled study.
March 2003, The Journal of clinical endocrinology and metabolism,
A Sommer, and S K Spratt, and G P Tatsuno, and T Tressel, and R Lee, and C A Maack
Recombinant, nonglycosylated human insulin-like growth factor-binding protein-3 (IGFBP-3) is degraded preferentially after administration to type II diabetics, resulting in increased endogenous glycosylated IGFBP-3.
December 2005, The Journal of clinical endocrinology and metabolism,
A Sommer, and S K Spratt, and G P Tatsuno, and T Tressel, and R Lee, and C A Maack
Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) functions as an IGF-reversible inhibitor of IGFBP-4 proteolysis.
November 1995, The Journal of biological chemistry,
A Sommer, and S K Spratt, and G P Tatsuno, and T Tressel, and R Lee, and C A Maack
Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) binds to fibronectin (FN): demonstration of IGF-I/IGFBP-3/fn ternary complexes in human plasma.
May 2001, The Journal of clinical endocrinology and metabolism,
A Sommer, and S K Spratt, and G P Tatsuno, and T Tressel, and R Lee, and C A Maack
Insulin-like growth factor-I (IGF-1), IGF-binding protein-3 (IGFBP-3) and mammographic features.
May 2012, Il Giornale di chirurgia,
A Sommer, and S K Spratt, and G P Tatsuno, and T Tressel, and R Lee, and C A Maack
Insulin-like growth factor binding protein (IGFBP)-3-bound IGF-I and IGFBP-3-bound IGF-II in growth hormone deficiency.
January 1999, Hormone research,
A Sommer, and S K Spratt, and G P Tatsuno, and T Tressel, and R Lee, and C A Maack
Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata.
November 1993, Human reproduction (Oxford, England),
A Sommer, and S K Spratt, and G P Tatsuno, and T Tressel, and R Lee, and C A Maack
IGF-I, IGF binding protein (IGFBP)-3, phosphoisoforms of IGFBP-1, and postnatal growth in very low birth weight infants.
May 2002, The Journal of clinical endocrinology and metabolism,
A Sommer, and S K Spratt, and G P Tatsuno, and T Tressel, and R Lee, and C A Maack
Analysis of circulating insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) in tobacco smokers and non-smokers.
June 2002, Tobacco induced diseases,
Copied contents to your clipboard!